Tag - HURA

Developments

TuHURA reveals initial data from study of adjunct therapy to Keytruda in MCC

TuHURA Biosciences (NASDAQ: HURA) announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment of metastatic Merkel Cell Carcinoma...

October 26, 2026

Markets

Rodman & Renshaw starts TuHURA at buy; PT $7

Rodman & Renshaw initiated coverage of TuHURA Biosciences (NASDAQ:HURA) with a “buy” rating and price target of $7.00. The stock closed at $3.15 on April 14th. TuHURA is currently undertaking a Phase 3 trial for its...

April 15, 2026

Tag - HURA

TuHURA reveals initial data from study of adjunct therapy to Keytruda in MCC

Rodman & Renshaw starts TuHURA at buy; PT $7

Subscribe